查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992614

脈絡膜新生血管市場：2026-2032年全球市場預測（依治療方法、藥物類別、疾病類型、病變類型、治療階段、通路和最終用戶分類）

Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，脈絡膜新生血管市場價值將達到 68.8 億美元，到 2026 年將成長至 73.6 億美元，到 2032 年將達到 116.9 億美元，複合年成長率為 7.86%。

主要市場統計數據
基準年 2025 68.8億美元
預計年份：2026年 73.6億美元
預測年份：2032年 116.9億美元
複合年成長率 (%) 7.86%

這是一篇清晰而全面的脈絡膜新生血管介紹，概述了其臨床特徵、診斷方法的進展以及不斷發展的治療前景。

脈絡膜新生血管（CNV）是影響脈絡膜-視網膜交界處最嚴重的併發症之一，可導致視力喪失、長期併發症，並影響醫療資源的分配。本文概述了CNV的臨床特徵、診斷途徑和目前治療標準，這些因素共同塑造了CNV的治療和商業性格局。多模態影像和早期檢測技術的進步顯著改善了患者的預後，使得更及時的干涉成為可能，從而改變了疾病的進展和患者的結果。然而，這些診斷技術的進步也增加了眼科醫師、視網膜專家和門診手術中心之間協調診療工作的複雜性。

重塑 CNV 治療的範式和相關人員的期望：從跨學科的觀點轉變科學、臨床和交付模式。

目前，脈絡膜新生血管（CNV）的治療正經歷著一場變革，這主要得益於科學創新、醫療服務模式的演變以及對以患者為中心的治療結果的重新關注。抗血管內皮生長因子（VEGF）藥物的生物學和分子工程改進延長了其作用持續時間並改善了其安全性，促使臨床醫生重新評估給藥間隔和隨訪方案。同時，來自真實世界數據和註冊登記的見解正在幫助最佳化治療方法，尤其是在病變形態複雜或對一線治療反應不佳的患者中。這些臨床趨勢與營運方式的改變交織在一起。雖然門診手術中心和眼科診所的設備越來越完善，能夠提供複雜的玻璃體內注射治療，但對於更嚴重的病例，醫院系統仍然發揮核心作用。

對 2025 年美國關稅環境將如何重塑 CNV 治療的供應鏈韌性、製造地和商業合約進行策略分析。

2025年美國關稅調整的累積影響正在改變脈絡膜新生血管（CNV）治療及相關醫療設備的成本結構和供應鏈動態。進口生技藥品成分、包裝材料和專用給藥裝置的關稅調整增加了部分製造商的採購成本，迫使他們重新評估籌資策略。因此，一些公司正在加快生技藥品生產關鍵流程的在地化進程，並實現供應商多元化，涵蓋多個地區，以降低貿易政策波動帶來的風險。此類供應鏈重組可能導致前置作業時間延長和短期庫存失衡，因此需要積極主動地進行庫存和分銷規劃。

將治療方法、分子分類、病變和疾病表現型、醫療保健環境和分銷管道與可操作的臨床和商業策略聯繫起來的詳細細分分析。

細分分析揭示了治療方法方案、分子分型、臨床症狀、病變特徵、治療線、分銷管道和終端用戶類型如何相互交織，共同塑造需求趨勢和治療管道。治療方法類型仍然是一個主要因素。抗VEGF療法在治療決策中佔據主導地位，阿維西普和雷珠單抗等藥物之間的分子水平差異會影響給藥間隔和患者追蹤。在某些醫療機構中，Bevacizumab因其成本效益而仍然重要，而具有改良分子結構的新型入門級藥物旨在延長療效持續時間並提高安全性。動態療法和抗VEGF藥物的聯合療法被選擇性地用於某些難治性或非典型病變，而基於維替泊芬的動態在某些病變亞型中仍然發揮作用。

關於 CNV，它是一種區域策略展望，旨在協調全球主要醫療保健區域內臨床實踐的多樣性、監管差異和供應鏈現實。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、監管管道和商業模式均產生顯著影響。在美洲，先進的視網膜醫療基礎設施和積極的都市區創新正在塑造市場發展，但支付方的複雜性和報銷政策的差異導致准入管道不均，因此需要製定個性化的打入市場策略。相較之下，歐洲、中東和非洲的管理體制和醫療保健財務模式各不相同，一些市場正在快速接受先進的生技藥品，而其他市場則受到預算上限的限制。應對這些差異需要細緻的溝通和證據生成，並根據具體國家情況進行調整，以支持報銷申請。亞太地區呈現出複雜的格局，龐大的病患群體和不斷成長的專科醫生數量與採購方式、價格敏感度和監管時間表的差異並存。在地化生產和區域夥伴關係對於商業性成功至關重要。

企業級競爭對手強調分子層級創新、真實世界證據、病患支持和供應鏈韌性，以此作為 CNV 差異化的基礎。

企業層面的關鍵趨勢集中在分子設計、生命週期管理和患者支援基礎設施的創新。研發人員正致力於開發新一代抗VEGF藥物，以延長保存期限、最佳化安全性，並透過獨特的作用機制和劑型實現差異化。策略重點包括建立強大的真實世界數據專案以驗證療效對比，建立全面的患者支援和用藥依從性服務，以及投資於生產冗餘以降低供應風險。隨著各公司努力簡化產品獲取流程並克服處理複雜生技藥品相關的物流挑戰，創新製藥公司與專業分銷商和醫院系統之間的夥伴關係變得日益重要。

行業領導者利用可操作和優先考慮的建議，來協調證據生成、製造韌性、准入計劃和支付方合作，從而實現 CNV 的成功。

為了將本報告的洞見轉化為實際營運優勢，產業領導者應優先考慮一系列切實可行的舉措，使臨床差異化與商業性可行性相契合。首先，應將實證研究工作重點放在直接比較試驗和真實世界比較研究上，以明確不同病變亞型和治療方案的治療定位。這些證據將有助於加強與支付方的溝通，並提升臨床醫師的信心。其次，應投資建立靈活的生產系統以及區域填充和包裝能力，以減輕關稅中斷對供應鏈的影響，並縮短關鍵物資的前置作業時間。第三，應根據不同的分銷管道和終端用戶的實際情況，量身定做准入和患者支持計劃，確保門診手術中心和眼科診所獲得後勤和教育支持，從而最佳化患者的用藥依從性和治療效果。

採用嚴謹的混合調查方法，結合關鍵相關人員的訪談和系統的二手文獻綜述，並輔以可靠的檢驗和品管。

本分析的調查方法整合了第一手和第二手調查，以確保其可靠性、有效性和可操作性。第一手調查包括對視網膜專家、醫院藥劑師、診所管理人員和保險公司代表進行半結構式訪談，以收集他們對治療決策、營運限制和就醫挑戰的直接看法。第二手調查包括對同行評審的臨床文獻、監管申報文件、臨床實驗室註冊數據以及專業學會發布的公開指南進行系統性回顧，以確定治療模式和特異性病變的治療結果。數據三角檢驗將定性研究結果與已發表的臨床證據相結合，以檢驗新出現的主題並識別臨床實驗室人群與臨床實踐之間的差異。

要將慢性非獸醫疾病 (CNV) 治療的進步轉化為永續的患者療效和商業性成功，必須將臨床創新、營運韌性和保險公司合作策略進行明確的整合。

總之，CNV（血管內皮生長因子）是一個科學和商業性都快速發展的領域，患者能否獲得治療以及治療效果取決於臨床創新、供應鏈策略和支付方合作的綜合作用。抗VEGF生物學和輔助性治療的進步使得更個人化的治療模式成為可能，但這些機會必須輔以實證醫學證據的累積、生產能力的提升以及對目標市場准入計畫的投入。價格趨勢和區域監管的複雜性進一步增加了商業風險，但企業可以透過採購多元化、區域夥伴關係和積極的支付方策略來降低這些風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 脈絡膜新生血管市場：依治療方法

  • 抗 VEGF 療法
    • 阿柏西普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 康維賽特
    • 雷尼珠單抗
  • 聯合治療
  • 動態療法

第9章：脈絡膜新生血管市場：依藥物類別分類

  • 融合蛋白
  • 單株抗體

第10章 脈絡膜新生血管市場：依疾病類型分類

  • 新生血管性老年黃斑部病變老齡化
  • 病理性近視

第11章：脈絡膜新生血管市場：依病變類型分類

  • 典型拷貝數變異
  • 混合拷貝數變異
  • 潛在拷貝數變異

第12章 脈絡膜新生血管市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第13章：脈絡膜新生血管市場：依通路分類

  • 線上
  • 離線

第14章 脈絡膜新生血管市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第15章 脈絡膜新生血管市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 脈絡膜新生血管市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 脈絡膜新生血管市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國脈絡膜新生血管市場

第19章：中國脈絡膜新生血管市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adverum BIoTechnologies
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch+Lomb Corporation
  • Bausch Health
  • Bayer AG
  • Biogen, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clearside Biomedical
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Iveric Bio
  • Kodiak Sciences
  • Kodiax Pharmaceuticals
  • Novartis AG
  • PulseSight Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis.
  • Sandoz Inc.
  • Santen Pharmaceutical Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market was valued at USD 6.88 billion in 2025 and is projected to grow to USD 7.36 billion in 2026, with a CAGR of 7.86%, reaching USD 11.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.88 billion
Estimated Year [2026] USD 7.36 billion
Forecast Year [2032] USD 11.69 billion
CAGR (%) 7.86%

A clear and comprehensive introduction to choroidal neovascularization that frames clinical characteristics, diagnostic improvements, and the evolving treatment landscape

Choroidal neovascularization (CNV) remains one of the most consequential complications affecting the choroid-retina interface, with implications for vision loss, long-term morbidity, and healthcare resource allocation. This introduction distills the clinical characteristics, diagnostic pathways, and contemporary standards of care that frame the therapeutic and commercial environment. Advances in multimodal imaging and earlier detection have reshaped patient journeys, enabling more timely interventions that alter disease trajectories and patient outcomes. These diagnostic gains, however, have increased the complexity of care coordination among ophthalmologists, retinal specialists, and ambulatory surgical centers.

Concurrently, treatment paradigms have evolved from focal therapies toward sustained biologic modulation of angiogenic pathways. Anti-VEGF agents have become central to clinical practice, while adjunctive approaches, including combination regimens and photodynamic therapy, persist in specific phenotypes or refractory cases. Payer policies and reimbursement coding have not always moved in lockstep with clinical innovation, creating variability in access and treatment continuity. As a result, stakeholders must navigate an intricate interplay between therapeutic efficacy, delivery logistics, and economic considerations when designing clinical programs and commercial strategies. This overview establishes the clinical and operational context necessary to evaluate subsequent sections on market shifts, segmentation insights, and strategic recommendations.

An interdisciplinary view of transformative scientific, clinical, and delivery-model shifts reshaping CNV treatment paradigms and stakeholder expectations

The landscape for CNV treatment is experiencing transformative shifts driven by scientific innovation, changing care delivery models, and a renewed focus on patient-centric outcomes. Biologic refinement and molecular engineering of anti-VEGF agents have extended durability and modified safety profiles, prompting clinicians to rethink dosing intervals and follow-up regimens. At the same time, real-world evidence and registry-driven insights are informing more nuanced therapy selection, especially for patients with complex lesion morphologies or those who demonstrate suboptimal response to first-line agents. These clinical dynamics are intersecting with operational changes: ambulatory surgical centers and ophthalmology clinics are increasingly equipped to deliver complex intravitreal therapies, while hospital systems continue to play a central role for higher-acuity presentations.

In parallel, payer scrutiny and value-based contracting conversations are influencing formulary positioning and access pathways. Manufacturers are responding with differentiated patient support programs and innovative distribution partnerships to reduce barriers to adherence. Technological advances in imaging and telemedicine have further enabled remote monitoring, which can reduce patient burden and improve adherence, but also require investment in interoperable systems and clinician training. Taken together, these shifts demand cross-functional strategies that align clinical differentiation, supply chain reliability, and stakeholder engagement to capitalize on therapeutic advances while safeguarding patient access and continuity of care.

A strategic analysis of how the 2025 United States tariff environment is reshaping supply chain resilience, manufacturing footprints, and commercial contracting for CNV therapies

The cumulative impact of United States tariff changes in 2025 is altering cost structures and supply chain dynamics that underpin CNV therapeutics and related medical devices. Tariff adjustments on imported biologic components, packaging materials, and specialized delivery devices have elevated sourcing costs for certain manufacturers, prompting them to reassess procurement strategies. As a result, some firms are accelerating initiatives to localize critical steps of biologic manufacturing or to diversify supplier bases across multiple geographies to mitigate exposure to trade policy volatility. This reconfiguration of supply chains can increase lead times and create short-term inventory imbalances that require proactive inventory and distribution planning.

Moreover, tariff-driven cost pressures are influencing the calculus around pricing, patient assistance programs, and contracting with payers. Health systems and distributors may face incremental logistical costs that translate into negotiations over reimbursement and formulary placement. In response, manufacturers are exploring near-term tactics such as hedging procurement contracts, modifying packaging to reduce tariffable components, and investing in regional fill-and-finish capacity. While these steps can stabilize supply, they also require capital allocation and regulatory alignment. Ultimately, the tariff environment is accelerating strategic decisions around manufacturing footprint, commercial contracting, and collaboration with end users to preserve timely access for patients while maintaining sustainable commercial models.

Deep segmentation insights linking treatment types, molecular classes, lesion and disease phenotypes, care settings, and distribution pathways to actionable clinical and commercial strategies

Segmentation analysis reveals how therapeutic choices, molecular classes, clinical presentations, lesion characteristics, lines of therapy, distribution channels, and end-user types collectively shape demand dynamics and care pathways. Treatment type remains a primary axis: anti-VEGF therapy dominates therapeutic decision-making, with molecule-level differentiation among agents such as aflibercept and ranibizumab that influence dosing cadence and patient follow-up. Bevacizumab retains relevance through cost-driven use in certain settings, while newer entrants with modified molecular structures aim to extend durability or alter safety profiles. Combination approaches that integrate photodynamic therapy with anti-VEGF agents are selectively employed for specific refractory or atypical presentations, and standalone photodynamic therapy, anchored by verteporfin, maintains a role in certain lesion subtypes.

Drug class segmentation highlights the operational and regulatory differences between fusion proteins and monoclonal antibodies; manufacturing complexity, cold-chain requirements, and patent landscapes differ across these classes and inform commercialization strategies. Disease-type distinctions between neovascular age-related macular degeneration and pathologic myopia dictate patient populations, natural history, and therapeutic responsiveness, requiring tailored clinical protocols. Lesion-type categories such as classic, mixed, and occult choroidal neovascularization present unique prognostic and treatment-response considerations that clinicians factor into initial therapy selection and monitoring frequency. Line-of-therapy segmentation underscores differences in goals between first-line interventions aimed at rapid disease control and second- or third-line approaches focused on refractory disease management. Distribution channel nuances between hospital and retail pharmacies affect dispensing workflows, reimbursement processes, and patient access points. Finally, end-user segmentation-spanning ambulatory surgical centers, hospitals, and ophthalmology clinics-captures the diversity of care settings where CNV treatments are delivered, each with distinct operational constraints, clinician expertise, and patient throughput considerations. Synthesizing these segmentation layers enables stakeholders to align clinical trial design, commercial messaging, and service delivery models to specific patient and provider contexts.

Regional strategic perspectives that reconcile clinical practice diversity, regulatory variation, and supply chain realities across major global healthcare regions for CNV

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market evolution is shaped by advanced retinal care infrastructure and strong adoption of innovation in urban centers, while payer complexity and heterogeneous reimbursement policies create variable access pathways and necessitate tailored market access strategies. In contrast, Europe, Middle East & Africa encompasses diverse regulatory regimes and healthcare financing models, with some markets demonstrating rapid uptake of advanced biologics and others constrained by budget ceilings; these differences require nuanced country-level engagement and evidence generation to support reimbursement dossiers. Asia-Pacific presents a heterogeneous landscape where high-volume patient populations and growing specialist capacity coexist with differences in procurement practices, pricing sensitivity, and regulatory timelines; local manufacturing and regional partnerships can be decisive factors in commercial success.

Across these regions, differences in clinical practice patterns, imaging availability, and end-user capabilities influence treatment pathways and patient outcomes. Regional regulatory policies around biologics, biosimilars, and import controls interact with logistical realities to shape supply chain design and launch sequencing. Therefore, stakeholders must adopt regionally differentiated strategies that integrate health-economic evidence, local real-world data, and clinician engagement plans to ensure that therapeutic innovations translate into sustained clinical adoption and patient benefits.

Company-level competitive dynamics emphasizing molecular innovation, real-world evidence, patient support, and supply chain resilience as bases for differentiation in CNV

Key company-level dynamics center on innovation in molecule design, lifecycle management, and patient support infrastructure. Developers are advancing next-generation anti-VEGF agents that seek to extend durability, optimize safety, and differentiate via unique mechanisms or delivery formats. Strategic priorities include building robust real-world evidence programs to demonstrate comparative effectiveness, establishing comprehensive patient support and adherence services, and investing in manufacturing redundancy to reduce supply risk. Partnerships between innovator firms and specialty distributors or hospital systems are becoming more salient as companies seek to streamline product access and overcome logistical hurdles tied to complex biologic handling.

Competitive differentiation increasingly depends on the ability to demonstrate outcomes in varied lesion types and patient subsets, to engage payers through outcome-based arrangements, and to enable clinicians with practical tools for treatment decisions and imaging interpretation. Companies that successfully integrate clinical development with targeted health-economic data and that invest in scalable support programs for diverse care settings are best positioned to navigate reimbursement negotiations and to sustain adoption in the face of biosimilar or alternative therapeutic entrants. Observing these company behaviors provides a roadmap for supply chain investment, evidence-generation priorities, and commercial execution.

Actionable, prioritized recommendations for industry leaders to align evidence generation, manufacturing resilience, access programs, and payer engagement for CNV success

To translate the report's insights into operational advantage, industry leaders should prioritize a set of actionable initiatives that align clinical differentiation with commercial execution. First, concentrate evidence-generation efforts on head-to-head and real-world comparative studies that clarify therapeutic positioning across lesion subtypes and lines of therapy; such evidence will improve payer dialogues and clinician confidence. Second, invest in flexible manufacturing and regional fill-and-finish capabilities to reduce exposure to tariff-driven disruptions and to shorten lead times for critical supplies. Third, tailor access and patient support programs to the realities of different distribution channels and end users, ensuring that ambulatory surgical centers and ophthalmology clinics receive logistical and educational support to optimize adherence and outcomes.

Additionally, explore innovative contracting models with payers that tie reimbursement to measurable clinical outcomes, and deploy digital monitoring tools to support remote follow-up and adherence. Foster targeted partnerships with regional stakeholders to address regulatory and procurement heterogeneity, and design product launch sequencing that reflects regional readiness and infrastructure capacity. Finally, translate clinical differentiation into pragmatic clinician-facing resources-such as dosing algorithms and imaging interpretation guides-to reduce variation in care and to accelerate adoption in complex patient populations.

A rigorous, mixed-methods research methodology combining primary stakeholder interviews and systematic secondary evidence review with robust triangulation and quality controls

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure robustness, validity, and practical relevance. Primary research involved semi-structured interviews with retina specialists, hospital pharmacy directors, clinic administrators, and payers to capture firsthand perspectives on treatment decision-making, operational constraints, and access challenges. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and publicly available guidance from professional societies to map treatment paradigms and lesion-specific outcomes. Data triangulation combined qualitative insights with published clinical evidence to validate emergent themes and to surface discrepancies between clinical trial populations and real-world practice.

Quality control measures included cross-validation of interview findings across multiple stakeholder cohorts, transparent documentation of inclusion criteria for secondary sources, and sensitivity checks to assess the robustness of strategic conclusions. The methodology explicitly acknowledges limitations related to regional heterogeneity and evolving regulatory landscapes; where data gaps exist, the analysis highlights areas requiring further primary evidence generation. Ethical standards for primary research were maintained, with informed consent obtained for interviews and confidentiality assured for proprietary disclosures. This mixed-methods approach supports a balanced, evidence-informed perspective that is actionable for clinical, commercial, and policy stakeholders.

A conclusive synthesis of clinical innovation, operational resilience, and payer-aligned strategies to convert therapeutic advances in CNV into sustained patient and commercial outcomes

In conclusion, choroidal neovascularization remains a domain of rapid scientific and commercial evolution where clinical innovation, supply chain strategy, and payer engagement intersect to determine patient access and therapeutic success. Advances in anti-VEGF biology and adjunctive therapies are enabling more personalized treatment paradigms, but these opportunities must be matched by investments in evidence generation, manufacturing resilience, and targeted access programs. Tariff dynamics and regional regulatory complexity add layers of operational risk that companies can mitigate through diversified sourcing, regional partnerships, and proactive payer strategies.

Ultimately, organizations that synchronize clinical differentiation with pragmatic execution-through rigorous real-world studies, clinician-enabled adoption tools, and flexible commercial models-will achieve sustained adoption and deliver measurable patient benefit. The strategic recommendations and segmentation insights presented herein provide a framework to prioritize initiatives, align cross-functional teams, and convert clinical promise into enduring therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Choroidal Neovascularization Market, by Treatment Type

  • 8.1. Anti-Vegf Therapy
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Conbercept
    • 8.1.5. Ranibizumab
  • 8.2. Combination Therapy
  • 8.3. Photodynamic Therapy

9. Choroidal Neovascularization Market, by Drug Class

  • 9.1. Fusion Proteins
  • 9.2. Monoclonal Antibodies

10. Choroidal Neovascularization Market, by Disease Type

  • 10.1. Neovascular Amd
  • 10.2. Pathologic Myopia

11. Choroidal Neovascularization Market, by Lesion Type

  • 11.1. Classic Cnv
  • 11.2. Mixed Cnv
  • 11.3. Occult Cnv

12. Choroidal Neovascularization Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line

13. Choroidal Neovascularization Market, by Distribution Channel

  • 13.1. Online
  • 13.2. Offline

14. Choroidal Neovascularization Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Hospitals
  • 14.3. Ophthalmology Clinics

15. Choroidal Neovascularization Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Choroidal Neovascularization Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Choroidal Neovascularization Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Choroidal Neovascularization Market

19. China Choroidal Neovascularization Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Adverum Biotechnologies
  • 20.6. Apellis Pharmaceuticals, Inc.
  • 20.7. Astellas Pharma Inc.
  • 20.8. Bausch + Lomb Corporation
  • 20.9. Bausch Health
  • 20.10. Bayer AG
  • 20.11. Biogen, Inc.
  • 20.12. Chugai Pharmaceutical Co., Ltd.
  • 20.13. Clearside Biomedical
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. Genentech, Inc.
  • 20.16. Iveric Bio
  • 20.17. Kodiak Sciences
  • 20.18. Kodiax Pharmaceuticals
  • 20.19. Novartis AG
  • 20.20. PulseSight Therapeutics
  • 20.21. Regeneron Pharmaceuticals Inc.
  • 20.22. Regeneron Pharmaceuticals Inc.
  • 20.23. Samsung Bioepis.
  • 20.24. Sandoz Inc.
  • 20.25. Santen Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)